Total
0
Shares
Immutep (ASX:IMM) - CEO, Marc Voigt
CEO, Marc Voigt
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep (IMM) has enrolled and safely dosed patients for the second stage of its study on head and neck cancer
  • The company develops LAG-3-related immunotherapeutic products for treating cancer and autoimmune disease
  • The TACTI-002 phase two study evaluates second line head and neck squamous cell carcinoma (HNSCC) being treated with Immutep’s lead product candidate, eftilagimod alpha, in combination with MSD’s KEYTRUDA treatment
  • Immutep’s shares are up 1.23 per cent, trading at 41.0 cents


Sydney-based biotechnology company Immutep (IMM) has enrolled and safely dosed patients for the second stage of its study on head and neck cancer.

The company develops LAG-3-related immunotherapeutic products for treating cancer and autoimmune disease.

Specifically, Immutep’s TACTI-002 phase two study evaluates second line head and neck squamous cell carcinoma (HNSCC) being treated with Immutep’s lead product candidate, eftilagimod alpha, in combination with MSD’s KEYTRUDA treatment.

Immutep reported encouraging interim data from the study at the Society for Immunotherapy of Cancer 35th Anniversary 2020 Annual Meeting.

The recruitment of an additional 74 patients with first-line non-small-cell lung carcinoma (NSCLC) in accordance with the TACTI-002 collaboration trial expansion plans has commenced. Now, four more patients have been recruited, adding to the 36 patients already enrolled prior to the expansion.

In total, 40 of 110 patients with first-line NSCLC have now been recruited in part A of the TACTI-002 study.

The company expects to report more data from the trial in the first half of 2021.

Immutep’s shares are up 1.23 per cent, trading at 41 cents at 11:45 am AEDT.

IMM by the numbers
More From The Market Herald
Aussie Broadband (ASX:ABB) - Managing Director, Phillip Britt

" Aussie Broadband (ASX:ABB) confirms takeover talks with Over The Wire (ASX:OTW)

In response to an article by The Australian, Aussie Broadband (ABB) has confirmed it is in discussions with Over The Wire (OTW) regarding
Cashrewards (ASX:CRW) - CEO, Bernard Wilson

" ANZ’s (ASZ:ANZ) investment arm to buy Cashrewards (ASX:CRW)

ANZ’s (ANZ) investment arm will aim to buy all of the share in fellow ASX-lister Cashrewards (CRW).
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.